HCT using alternative donors in myelofibrosis
| Reference . | Donor type . | n . | Conditioning . | GVHD prophylaxis . | OS (95% CI) . | NRM (95% CI) . | Graft failure . | GVHD . |
|---|---|---|---|---|---|---|---|---|
| Raj et al. (2019)55 | Mismatched related donor | 56 | MAC (70%)/RIC (30%) | PTCy in 79% | 56% (41%-70%) at 2 y | 38% (24%-51%) at 2 y | Primary 9% Secondary 13% | aGVHD* 28% cGVHD 45% at 1 y |
| Murata et al. (2019)56 | Unrelated cord blood | 13 | — | — | 48% at 1 y 27% at 4 y | 41% (22%-60%) at 1 y 62% (35%-81%) at 4 y | — | aGVHD* 31% cGVHD 15% at 1 y |
| Kunte et al. (2020)54 | Haploidentical | 58 | NMA (52%)/RIC (45%) | PTCy in 100% | 69% (55%-80%) at 2 y | 21% (11%-34%) at 2 y | Primary 9% | aGVHD* 44% at 6 m cGVHD 31% at 2 y |
| Reference . | Donor type . | n . | Conditioning . | GVHD prophylaxis . | OS (95% CI) . | NRM (95% CI) . | Graft failure . | GVHD . |
|---|---|---|---|---|---|---|---|---|
| Raj et al. (2019)55 | Mismatched related donor | 56 | MAC (70%)/RIC (30%) | PTCy in 79% | 56% (41%-70%) at 2 y | 38% (24%-51%) at 2 y | Primary 9% Secondary 13% | aGVHD* 28% cGVHD 45% at 1 y |
| Murata et al. (2019)56 | Unrelated cord blood | 13 | — | — | 48% at 1 y 27% at 4 y | 41% (22%-60%) at 1 y 62% (35%-81%) at 4 y | — | aGVHD* 31% cGVHD 15% at 1 y |
| Kunte et al. (2020)54 | Haploidentical | 58 | NMA (52%)/RIC (45%) | PTCy in 100% | 69% (55%-80%) at 2 y | 21% (11%-34%) at 2 y | Primary 9% | aGVHD* 44% at 6 m cGVHD 31% at 2 y |
Acute GVHD encompasses grades II to IV.
MAC, myeloablative conditioning; NMA, non-myeloablative; PTCy, posttransplant cyclophosphamide.